Use of combination adriamycin (NSC-123127) and DTIC (NSC-45388) in children with advanced stage IV neuroblastoma.
Adriamycin and DTIC were used in combination because of their reported effectiveness in neuroblastoma when administered as single agents and because of the poor survival rate of patients with this malignancy in its disseminated stage. Eighteen patients with previously treated stage IV neuroblastoma received this combination chemotherapy every 21 days. Two to eight courses were administered. Two partial and no complete remissions were seen. Mild to moderate gastrointestinal and hematologic toxicity was observed.
D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003606:Dacarbazine / Q000009:adverse effects / Q000627:therapeutic use*; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009447:Neuroblastoma / Q000188:drug therapy*; D012075:Remission, Spontaneous; D014226:Triazenes / Q000627:therapeutic use*
D014226:Triazenes; D003606:Dacarbazine; D004317:Doxorubicin